BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a ...
Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in glaucoma expected to commence in first quarter of 2023Acquired corneal ...
Two New Independent Directors Enhance Extensive Insurance, Finance, Data Privacy and Security, Legal, and Governance Expertise on the Board To File Preliminary Proxy Statement That Includes Proposals to Further Enhance ...
Copyright © 2015 - 2021 Lifecarenews.in
